PeptideMeter
Runs dual-wavelength detection as standard and reports named related substances rather than totals only. 1,116 reports in the index — 17.0 % of the total.
Identification and method basis
- Laboratory
- PeptideMeter
- Short code in this index
- PeptideMeter
- Location
- Tallinn, Estonia
- Founded
- 2021
- Reports contributed
- 1,116
- Share of index
- 17.0%
- Purity gradient
- 28min
- Mass resolution
- High resolution (ESI-TOF / QTOF)
- Stated turnaround
- 4–8 business days
- Measured offset vs reference
- -0.037 pp
- Within-lab repeatability
- 0.22pp
PeptideMeter's distinguishing practice is that it reports related substances by name, with retention times, rather than reporting a total impurity figure. For the index this is disproportionately valuable: a named impurity table is what makes the impurity-reconciliation check on each report meaningful, and it is what allows two batches from different suppliers to be identified as the same bulk from their impurity fingerprints. Twenty-nine such cross-links exist in the index and all but four were established from PeptideMeter data.
Dual-wavelength detection at 214 nm and 280 nm is also standard here, which matters for compounds containing tryptophan or tyrosine: the 280 nm trace distinguishes an aromatic impurity from a non-aromatic one without requiring MS, and it makes oxidation products easier to assign.
Measured bias against the reference is −0.05 pp with 95 % limits of agreement of ±0.44 pp, on 214 paired comparisons. That is statistically indistinguishable from zero and the index treats PeptideMeter and Janoshik results as directly comparable.
Methods offered
What a laboratory can measure decides what a record can establish. A submission that orders only purity produces a record that names nothing.
- RP-HPLC purity (%area, 214 nm and 280 nm)
- LC-MS identity (ESI-QTOF)
- related-substances profiling with named impurities
- Karl Fischer water
- peptide content by amino-acid analysis
What this laboratory has measured
| Compound class | Reports | Median purity | Method suitability |
|---|---|---|---|
| Incretin analogues and co-agonists | 392 | 98.55 | ADEQUATE |
| Growth-hormone axis peptides | 216 | 99.10 | ADEQUATE |
| Tissue-repair and immunomodulatory peptides | 195 | 99.29 | ADEQUATE |
| Neuroactive and cognitive peptides | 75 | 99.32 | ADEQUATE |
| Metabolic and mitochondrial peptides | 64 | 99.22 | ADEQUATE |
| Melanocortin-receptor peptides | 61 | 99.28 | ADEQUATE |
| Non-peptide adjuncts | 61 | 99.42 | ADEQUATE |
| Short bioregulator peptides | 36 | 99.40 | ADEQUATE |
| Hypothalamic and posterior-pituitary hormones | 16 | 99.50 | ADEQUATE |
| Most-tested compounds here | Reports | Median purity |
|---|---|---|
| Tirzepatide | 146 | 98.41 |
| Semaglutide | 118 | 98.76 |
| Retatrutide | 76 | 98.26 |
| BPC-157 | 74 | 99.06 |
| TB-500 | 47 | 99.51 |
| CJC-1295 (no DAC) | 44 | 99.07 |
| GHRP-6 | 42 | 99.50 |
| Semax | 39 | 99.27 |
| MK-677 (Ibutamoren mesylate) | 33 | 99.45 |
| Ipamorelin | 32 | 99.44 |
| PT-141 (Bremelanotide) | 30 | 99.43 |
| SS-31 (Elamipretide) | 23 | 99.47 |
| CJC-1295 with DAC | 21 | 98.87 |
| Selank | 21 | 99.53 |
| AOD-9604 | 21 | 99.00 |
| ARA-290 | 21 | 99.50 |
Agreement with the other laboratories
Each row is a paired analysis: batches where this laboratory and another one both assayed the same physical lot. A difference on a matched pair is bias plus noise, and it is the only clean way to compare laboratories.
| Against | Paired lots | Mean difference (pp) | 95 % limits of agreement | Within 0.5 pp |
|---|---|---|---|---|
| Janoshik | 558 | -0.037 | -0.55 to 0.47 | 93% |
| Medutest | 374 | -0.087 | -0.78 to 0.60 | 85% |
| VendorInvestigate | 275 | +0.105 | -0.63 to 0.84 | 82% |
| Nordanalyt | 273 | -0.058 | -0.62 to 0.50 | 89% |
| Kestrel | 217 | -0.402 | -1.38 to 0.57 | 64% |
Positive means PeptideMeter read higher. The full paired analysis, with its assumptions →
Provenance of what this laboratory receives
A laboratory that mostly receives supplier-supplied samples produces a record set with a known upward pressure on it, however good its analysis is. This is a property of the submission channel and not of the laboratory.
| Provenance | Reports | Share | Evidentiary weight | |
|---|---|---|---|---|
| Buyer-sourced | 970 | 86.9% | Strongest available evidence in this index. | |
| Supplier-supplied | 81 | 7.3% | Weaker evidence. Read with the caveat below. | |
| Laboratory-retained | 65 | 5.8% | Provenance documented, selection uncontrolled. |